We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

251 hedge funds and large institutions have $4.98B invested in Iovance Biotherapeutics in 2021 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 98 increasing their positions, 77 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more call options, than puts

Call options by funds: $37.9M | Put options by funds: $18.9M

27% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 77

5.5% more ownership

Funds ownership: 101.41% → 106.9% (+5.5%)

7% less funds holding

Funds holding: 269 → 251 (-18)

28% less capital invested

Capital invested by funds: $6.9B → $4.98B (-$1.92B)

29% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 58

36% less funds holding in top 10

Funds holding in top 10: 11 → 7 (-4)

Holders
251
Holders Change
-18
Holders Change %
-6.69%
% of All Funds
4.41%
Holding in Top 10
7
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-36.36%
% of All Funds
0.12%
New
41
Increased
98
Reduced
77
Closed
58
Calls
$37.9M
Puts
$18.9M
Net Calls
+$18.9M
Net Calls Change
-$23.1M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$184M
2
Deutsche Bank
Deutsche Bank
Germany
+$181M
3
CS
Credit Suisse
Switzerland
+$98.2M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$67.8M
5
Goldman Sachs
Goldman Sachs
New York
+$48.6M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$93.1M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$86.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$53.9M
4
FCM
Farallon Capital Management
California
-$51.8M
5
CCM
Consonance Capital Management
New York
-$38.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
State of Wisconsin Investment Board
151
State of Wisconsin Investment Board
Wisconsin
$553K -$10.2K -245 -1%
P8IP
152
Pier 88 Investment Partners
California
$549K -$131K -3,165 -15%
CAN
153
Claraphi Advisory Network
United States
$548K +$9.45K +228 +1%
PP
154
PDT Partners
New York
$539K +$706K +17,030 New
Public Employees Retirement Association of Colorado
155
Public Employees Retirement Association of Colorado
Colorado
$531K – – –
OC
156
Oppenheimer & Co
New York
$528K -$99K -2,389 -13%
CIA
157
Capital Impact Advisors
Massachusetts
$524K -$2.63M -63,439 -79%
DTL
158
Dynamic Technology Lab
Singapore
$519K +$679K +16,388 New
SMH
159
Sanders Morris Harris
Texas
$502K – – –
PWA
160
Phoenix Wealth Advisors
North Carolina
$482K +$121K +2,914 +24%
X
161
Xponance
Pennsylvania
$460K +$8.08K +195 +1%
Group One Trading
162
Group One Trading
Illinois
$444K +$582K +14,035 New
MAM
163
Meeder Asset Management
Ohio
$439K +$575K +13,881 New
HCS
164
Himension Capital (Singapore)
Singapore
$437K – – –
Envestnet Asset Management
165
Envestnet Asset Management
Illinois
$424K +$332 +8 +0.1%
Zurich Cantonal Bank
166
Zurich Cantonal Bank
Switzerland
$416K -$31K -747 -5%
TCM
167
Traynor Capital Management
Pennsylvania
$410K +$538K +12,975 New
ACM
168
AlphaCrest Capital Management
New York
$408K +$33.2K +800 +7%
JMPWA
169
JP Morgan Private Wealth Advisors
California
$398K +$5.64K +136 +1%
AC
170
Athanor Capital
New York
$383K -$967K -23,327 -66%
Teacher Retirement System of Texas
171
Teacher Retirement System of Texas
Texas
$382K +$93.6K +2,258 +23%
Nomura Holdings
172
Nomura Holdings
Japan
$380K +$497K +12,000 New
B
173
Bailard
California
$370K – – –
BC
174
Bridgefront Capital
Texas
$370K +$484K +11,678 New
PI
175
PEAK6 Investments
Illinois
$361K +$472K +11,393 New
5 6
7
8 9

IOVA Hedge Fund Activity: Q1 2021 in Review

251 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2021, worth a combined $4.98B — down 28% from $6.9B a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of IOVA and 41 opened new positions — a net loss of 17 holders — while 77 trimmed existing stakes and 98 added.

The largest buyer was ARK Investment Management, adding an estimated $184M. The largest seller was T. Rowe Price Associates, cutting an estimated $93.1M.

  • 251 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2021, down from 269 in Q4 2020.
  • Funds reported $4.98B of Iovance Biotherapeutics stock for Q1 2021, down 28% quarter-over-quarter.
  • 41 funds opened new Iovance Biotherapeutics positions in Q1 2021 and 58 closed out, a net change of -17 holders.
  • The largest Iovance Biotherapeutics buyer in Q1 2021 was ARK Investment Management, an estimated $184M added.
  • The largest Iovance Biotherapeutics seller in Q1 2021 was T. Rowe Price Associates, an estimated $93.1M sold.

Based on aggregated 13F filings for Q1 2021.